Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20
What Is The Anticipated Size Of The Paroxysmal Nocturnal Hemoglobinuria (PNH) And Atypical Hemolytic Uremic Syndrome (aHUS) Market Over The Five-Year Period 2025–2029?
The market size for paroxysmal nocturnal hemoglobinuria (pnh) and atypical hemolytic uremic syndrome (ahus) has witnessed substantial growth over recent years. It is projected to increase from $5.57 billion in 2024 to $5.97 billion in 2025, achieving a compound annual growth rate (CAGR) of 7.1%. This historical expansion can be attributed to the rising prevalence of PNH and aHUS, increased investment in rare disease research, an escalating demand for targeted therapies, heightened awareness regarding PNH and aHUS, and the expanding adoption of complement inhibitors.
The market for paroxysmal nocturnal hemoglobinuria (pnh) and atypical hemolytic uremic syndrome (ahus) is anticipated to experience robust growth in the coming years. Its size is projected to reach $7.88 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 7.2%. This expansion during the forecast period can be attributed to an increase in regulatory approvals for novel treatments, burgeoning collaboration between biotechnology companies and research institutes, a surging demand for personalized medicine, elevated investment in rare disease startups, and an escalating number of clinical trials and research studies. Significant trends expected in the forecast period include advancements in complement inhibition therapies, the integration of gene therapy approaches, ongoing developments in personalized medicine, the adoption of technology-driven diagnostic tools, and the enhanced integration of technology for remote patient monitoring.
Unlock Your Free Sample Report for Exclusive Market Data:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24357&type=smp
Which Industry Drivers Are Expected To Accelerate The Paroxysmal Nocturnal Hemoglobinuria (PNH) And Atypical Hemolytic Uremic Syndrome (aHUS) Market From 2025 To 2029?
The anticipated expansion of the paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS) market is linked to the increasing occurrence of rare diseases. These conditions are defined as health issues impacting a small segment of the population, usually under 200,000 individuals, frequently noted for their intricacy, seriousness, and requirement for expert medical care. The surge in rare disease prevalence stems from enhanced diagnostic technologies, facilitating improved detection and identification of conditions that were previously not reported or unrecognized. Paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS) play a role in advancing the comprehension and management of rare diseases, offering understanding into their pathophysiology and prospective treatment goals for ailments with scarce therapeutic alternatives. For example, data from November 2024, released by the US-based federal agency Food and Drug Administration, indicated that over 7,000 rare diseases affected more than 30 million people in the United States. Consequently, the growing incidence of rare diseases is fueling the expansion of the paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS) market.
What Are The Emerging Segments Gaining Attention In The Paroxysmal Nocturnal Hemoglobinuria (PNH) And Atypical Hemolytic Uremic Syndrome (aHUS) Market?
The paroxysmal nocturnal hemoglobinuria (pnh) and atypical hemolytic uremic syndrome (ahus)market covered in this report is segmented –
1) By Type: Soliris; Ultomiris
2) By Disease Type: Paroxysmal Nocturnal Hemoglobinuria(PNH); Atypical Hemolytic Uremic Syndrome(aHUS)
3) By Treatment Type: Complement Inhibitors; Plasma Exchange Or Infusion; Other Symptomatic Treatments
4) By Diagnosis Method: Clinical Diagnosis; Genetic Testing; Biomarker Testing
5) By End-User: Hospitals; Specialty Clinics; Research Institutes; Other Users
Subsegments:
1) By Soliris: Eculizumab For PNH; Eculizumab For aHUS; Eculizumab Biosimilars
2) By Ultomiris: Ravulizumab For PNH; Ravulizumab For aHUS; Ravulizumab Extended-Interval Dosing
What Trends Are Redefining The Paroxysmal Nocturnal Hemoglobinuria (PNH) And Atypical Hemolytic Uremic Syndrome (aHUS) Market Dynamics?
Leading companies in the paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS) market are prioritizing the development of innovative products, such as complement inhibitors, to enhance treatment outcomes and patient convenience. Complement inhibitors are therapeutic agents that target and block specific elements of the complement system, an immune system component crucial for clearing pathogens and damaged cells. For example, in December 2023, Novartis AG, a Switzerland-based pharmaceutical company, secured U.S. Food and Drug Administration (FDA) approval for Fabhalta (iptacopan). This marked the introduction of the first oral monotherapy for adult paroxysmal nocturnal hemoglobinuria, delivering superior hemoglobin improvement without the necessity for transfusions. This novel complement inhibitor operates by inhibiting Factor B in the alternative complement pathway, offering comprehensive control over both intravascular and extravascular hemolysis. Its oral method of administration streamlines disease management and improves the quality of life for patients by alleviating the burdens associated with frequent infusions.
Which Leading Players Are Enhancing Their Paroxysmal Nocturnal Hemoglobinuria (PNH) And Atypical Hemolytic Uremic Syndrome (aHUS) Market Presence Worldwide?
Major companies operating in the paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS) market are Roche Holding AG, AstraZeneca plc, Novartis AG, Amgen Inc., Teva Pharmaceuticals Ltd., Regeneron Pharmaceuticals Inc., Chugai Pharmaceutical Co. Ltd., Alexion Pharmaceuticals Inc., UCB Pharma Limited, Alnylam Pharmaceuticals Inc., BioCryst Pharmaceuticals Inc., Genentech Inc., Omeros Corporation, CinnaGen Co., Apellis Pharmaceuticals Inc., CANbridge Pharmaceuticals Inc., Kira Pharmaceuticals, NovelMed Therapeutics Inc., Arrowhead Pharmaceuticals Inc., Akari Therapeutics plc
Download The Full Report For Exclusive Market Findings:
What Regional Growth Trends Are Shaping The Paroxysmal Nocturnal Hemoglobinuria (PNH) And Atypical Hemolytic Uremic Syndrome (aHUS) Market Outlook?
North America was the largest region in the paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Version Of The Paroxysmal Nocturnal Hemoglobinuria (PNH) And Atypical Hemolytic Uremic Syndrome (aHUS) Market Report:
https://www.thebusinessresearchcompany.com/customise?id=24357&type=smp
Browse Through More Reports Similar to the Global Paroxysmal Nocturnal Hemoglobinuria (PNH) And Atypical Hemolytic Uremic Syndrome (aHUS) Market 2025, By The Business Research Company
Acute Coronary Syndrome Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/acute-coronary-syndrome-global-market-report
Acute Respiratory Distress Syndrome Ards Global Market Report 2025
Antiphospholipid Syndrome Treatment Global Market Report 2025
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model